|
1
|
Hoofnagle JH and Björnsson ES:
Drug-induced liver injury - types and phenotypes. N Engl J Med.
381:264–273. 2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Aithal GP, Watkins PB, Andrade RJ, Larrey
D, Molokhia M, Takikawa H, Hunt CM, Wilke RA, Avigan M, Kaplowitz
N, et al: Case definition and phenotype standardization in
drug-induced liver injury. Clin Pharmacol Ther. 89:806–815.
2011.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Chung Y, Morrison M, Zen Y and Heneghan
MA: Defining characteristics and long-term prognosis of
drug-induced autoimmune-like hepatitis: A retrospective cohort
study. United European Gastroenterol J. 12:66–75. 2024.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Andrade RJ, Aithal GP, De Boer YS, Liberal
R, Gerbes A, Regev A, Terziroli Beretta-Piccoli B, Schramm C,
Kleiner DE, De Martin E, et al: Nomenclature, diagnosis and
management of drug-induced autoimmune-like hepatitis (DI-ALH): An
expert opinion meeting report. J Hepatol. 79:853–866.
2023.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Graham J, Mushin M and Kirkpatrick P:
Oxaliplatin. Nat Rev Drug Discov. 3:11–12. 2004.
|
|
6
|
de Gramont A, Figer A, Seymour M, Homerin
M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer
G, et al: Leucovorin and fluorouracil with or without oxaliplatin
as first-line treatment in advanced colorectal cancer. J Clin
Oncol. 41:5080–5089. 2023.
|
|
7
|
Lieu C, Kennedy EB, Bergsland E, Berlin J,
George TJ, Gill S, Gold PJ, Hantel A, Jones L, Mahmoud N, et al:
Duration of oxaliplatin-containing adjuvant therapy for stage III
colon cancer: ASCO clinical practice guideline. J Clin Oncol.
37:1436–1447. 2019.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Kang L, Tian Y, Xu S and Chen H:
Oxaliplatin-induced peripheral neuropathy: Clinical features,
mechanisms, prevention and treatment. J Neurol. 268:3269–3282.
2021.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Huang R, Cai Y, He Y, Yu Z, Zhao L, Wang
T, Shangguan X, Zhao Y, Chen Z, Chen Y and Zhang C: Predictive
model of oxaliplatin-induced liver injury based on artificial
neural network and logistic regression. J Clin Transl Hepatol.
11:1455–1464. 2023.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Yu Z, Huang R, Zhao L, Wang X, Shangguan
X, Li W, Li M, Yin X, Zhang C and Liu D: Safety profile of
oxaliplatin in 3,687 patients with cancer in China: A
post-marketing surveillance study. Front Oncol.
11(757196)2021.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Amin MB, Greene FL, Edge SB, Compton CC,
Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR and
Winchester DP: The eighth edition AJCC cancer staging manual:
Continuing to build a bridge from a population-based to a more
‘personalized’ approach to cancer staging. CA Cancer J Clin.
67:93–99. 2017.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Benson AB, Venook AP, Adam M, Chang G,
Chen YJ, Ciombor KK, Cohen SA, Cooper HS, Deming D, Garrido-Laguna
I, et al: NCCN guidelines® insights: Rectal cancer, version 3.2024.
J Natl Compr Canc Netw. 22:366–375. 2024.PubMed/NCBI View Article : Google Scholar
|
|
13
|
European Association for the Study of the
Liver. EASL clinical practice guidelines: Drug-induced liver
injury. J Hepatol. 70:1222–1261. 2019.PubMed/NCBI View Article : Google Scholar
|
|
14
|
European Association for the Study of the
Liver. EASL clinical practice guidelines: Autoimmune hepatitis. J
Hepatol. 63:971–1004. 2015.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Danan G and Benichou C: Causality
assessment of adverse reactions to drugs-I. A novel method based on
the conclusions of international consensus meetings: Application to
drug-induced liver injuries. J Clin Epidemiol. 46:1323–1330.
1993.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Rockey DC, Seeff LB, Rochon J, Freston J,
Chalasani N, Bonacini M, Fontana RJ and Hayashi PH: US Drug-Induced
Liver Injury Network. Causality assessment in drug-induced liver
injury using a structured expert opinion process: Comparison to the
roussel-uclaf causality assessment method. Hepatology.
51:2117–2126. 2010.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Hayashi PH, Lucena MI and Fontana RJ:
RECAM: A new and improved, computerized causality assessment tool
for DILI diagnosis. Am J Gastroenterol. 117:1387–1389.
2022.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Björnsson E, Talwalkar J, Treeprasertsuk
S, Kamath PS, Takahashi N, Sanderson S, Neuhauser M and Lindor K:
Drug-induced autoimmune hepatitis: Clinical characteristics and
prognosis. Hepatology. 51:2040–2048. 2010.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Hoofnagle JH, Serrano J, Knoben JE and
Navarro VJ: LiverTox: A website on drug-induced liver injury.
Hepatology. 57:873–874. 2013.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Rubbia-Brandt L, Lauwers GY, Wang H, Majno
PE, Tanabe K, Zhu AX, Brezault C, Soubrane O, Abdalla EK, Vauthey
J, et al: Sinusoidal obstruction syndrome and nodular regenerative
hyperplasia are frequent oxaliplatin-associated liver lesions and
partially prevented by bevacizumab in patients with hepatic
colorectal metastasis. Histopathology. 56:430–439. 2010.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Benavides M, Pericay C, Valladares-Ayerbes
M, Gil-Calle S, Massutí B, Aparicio J, Dueñas R, González-Flores E,
Carrato A, Marcuello E, et al: Oxaliplatin in combination with
infusional 5-fluorouracil as first-line chemotherapy for elderly
patients with metastatic colorectal cancer: A phase II study of the
Spanish cooperative group for the treatment of digestive tumors.
Clin Colorectal Cancer. 11:200–206. 2012.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Robinson SM, Wilson CH, Burt AD, Manas DM
and White SA: Chemotherapy-associated liver injury in patients with
colorectal liver metastases: A systematic review and meta-analysis.
Ann Surg Oncol. 19:4287–4299. 2012.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Robinson SM, Mann J, Vasilaki A, Mathers
J, Burt AD, Oakley F, White SA and Mann DA: Pathogenesis of FOLFOX
induced sinusoidal obstruction syndrome in a murine chemotherapy
model. J Hepatol. 59:318–326. 2013.PubMed/NCBI View Article : Google Scholar
|
